Animab, a company pioneering oral monoclonal antibody solutions for production animals, has named Jan Spaas as the new Chairman of its Board. The company, which utilizes innovative technology to target harmful pathogens in animal intestines, aims to commercialize its products with Spaas’ extensive experience in veterinary biotech. Spaas has previously served in significant roles at Global Stem Cell Technology and Boehringer Ingelheim, bringing a wealth of experience in research, development, and biotech innovation. His appointment comes as the company seeks to advance its strategic goals and commercialization efforts, succeeding Patrik Keereman, who has been instrumental since the company’s inception.

Biotechnology, Animal Health, Private Equity,Belgium, Global